Medtronic Introduces Innovative PulseSelect Device for Atrial Fibrillation Treatment in India, ETHealthworld
New Delhi: Medtronic has launched the “PulseSelect” system in India to treat atrial fibrillation (AFib), the most common heart disorder leading to increased risks of strokes.
The PulseSelect is a Pulsed Field Ablation (PFA) system designed to treat atrial fibrillation which affects millions of people in India, exposing them to the risk of strokes.
According to the global medical technology firm, PFA uses short electrical pulses instead of thermal energy used by traditional treatments like radiofrequency ablation or cryoablation, and reduces the risk of damage to a patient’s tissues.
Chandrashekhar Jaiman, Senior Director, Cardiovascular Surgery & Electrophysiology Therapies, Medtronic India said, “India is witnessing a significant rise in stroke and cardiac diseases, with atrial fibrillation (AFib) emerging as a major and often underrecognized contributor to this growing burden.”
“AFib significantly increases the risk of stroke, heart failure, and other serious cardiovascular complications if left untreated, yet it remains severely underdiagnosed and undertreated in the country due to limited awareness and gaps in diagnosis and care pathways. While technology alone cannot solve these systemic challenges, continued innovation plays an important role in strengthening the overall care ecosystem.”
He added, “The launch of the PulseSelect system represents an important step in expanding the treatment options available to physicians in India. At Medtronic, patients remain at the center of everything we do. By introducing this next-generation technology, we aim to support physicians with advanced tools that can help improve procedural precision, enhance safety, and ultimately improve outcomes and quality of life for people living with atrial fibrillation.”
